Novabridge Biosciences (NBP) — SEC Filings

Overview

Novabridge Biosciences (NBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 22, 2026: NovaBridge Biosciences filed a Form 6-K on April 22, 2026, reporting information as a foreign issuer. The filing includes documents such as a press release and exhibits, with a total submission size of 693,270 bytes.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bullish, 46 neutral, 1 mixed. The dominant filing sentiment for Novabridge Biosciences is neutral.

Filing Type Overview

Novabridge Biosciences (NBP) has filed 49 6-K, 1 20-F with the SEC between Jun 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• NovaBridge Biosciences Files 6-K Report — 6-K · Apr 22, 2026 Risk: low
  NovaBridge Biosciences filed a Form 6-K on April 22, 2026, reporting information as a foreign issuer. The filing includes documents such as a press release and
• NovaBridge Biosciences Files 6-K for Q3 2025 — 6-K · Dec 18, 2025 Risk: low
  NovaBridge Biosciences filed a 6-K report as of September 30, 2025. The report details financial information and corporate events. Notably, the company was form
• NovaBridge Biosciences Files 6-K for ESMO IO Poster Release — 6-K · Dec 10, 2025 Risk: low
  On December 10, 2025, NovaBridge Biosciences filed a Form 6-K to report the issuance of a press release regarding an ESMO IO poster presentation. The filing its
• 6-K Filing — 6-K · Dec 4, 2025
• NovaBridge Biosciences Files 6-K, Incorporates Exhibits — 6-K · Oct 31, 2025 Risk: low
  NovaBridge Biosciences filed a Form 6-K on October 31, 2025, reporting for the month of October 2025. The filing indicates that Exhibit 99.1 is incorporated by
• NovaBridge Biosciences Files 6-K with Assignment Agreement — 6-K · Oct 30, 2025 Risk: medium
  NovaBridge Biosciences, formerly I-Mab, filed a Form 6-K on October 30, 2025. The filing includes an Assignment and Assumption Agreement between Visara, Inc. an
• NovaBridge Biosciences Shareholder Approval Filed — 6-K · Oct 29, 2025 Risk: low
  NovaBridge Biosciences filed a Form 6-K on October 29, 2025, reporting on events from October 2025. The filing indicates that on October 24, 2025, the company's
• I-Mab Announces Acquisition of Hong Kong Subsidiary — 6-K · Oct 28, 2025 Risk: medium
  On October 28, 2025, I-Mab announced the closing of a transaction where its wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited, was acquired. The filing
• I-Mab Files 6-K, Incorporates Exhibits into F-3 — 6-K · Oct 24, 2025 Risk: low
  I-Mab filed a Form 6-K on October 24, 2025, to report information for the month of October 2025. This filing includes Exhibit 99.1, which is incorporated by ref
• I-Mab Files 6-K for October 2025 — 6-K · Oct 23, 2025 Risk: low
  I-Mab filed a Form 6-K on October 23, 2025, to report information for the month of October 2025. The filing incorporates by reference Exhibit 99.1 into its Regi
• I-Mab Files 6-K, Incorporates Exhibit 99.1 — 6-K · Oct 22, 2025 Risk: low
  I-Mab (File No. 333-286954) filed a Form 6-K on October 22, 2025, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3
• I-Mab Unveils New Business Model — 6-K · Oct 16, 2025 Risk: medium
  On October 16, 2025, I-Mab announced a new business model focused on identifying and advancing high-value therapeutic assets. This strategic shift aims to lever
• I-Mab Files 6-K Report for Q2 2025 — 6-K · Oct 6, 2025 Risk: low
  I-Mab filed a 6-K report on October 6, 2025, for the period ending June 30, 2025. The filing includes financial information and details related to share-based c
• I-Mab Schedules Extraordinary General Meeting for Oct 24 — 6-K · Sep 24, 2025 Risk: low
  I-Mab announced it will hold an Extraordinary General Meeting of Shareholders on October 24, 2025, at 10:00 AM. The purpose of this meeting is to vote on certai
• I-Mab Appoints Wei Fu as Executive Chairman — 6-K · Sep 8, 2025 Risk: low
  On September 3, 2025, I-Mab's Board of Directors appointed Mr. Wei Fu as the Executive Chairman. The filing also notes the appointment of other officers, though
• I-Mab Appoints Two New Directors to Board — 6-K · Aug 25, 2025 Risk: low
  On August 22, 2025, I-Mab appointed Dr. Robert Lenz and Ms. Xin Li to its Board of Directors. This filing is a Form 6-K, reporting a significant change in the c
• I-Mab Files 6-K with Q2 2025 Financial Results — 6-K · Aug 20, 2025 Risk: low
  On August 20, 2025, I-Mab (the "Registrant") filed a Form 6-K to furnish a press release announcing its financial results for the three and six months ended Jun
• I-Mab Files 6-K, Incorporates Exhibit 99.1 — 6-K · Aug 11, 2025 Risk: low
  I-Mab, a biopharmaceutical company, filed a Form 6-K on August 11, 2025, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on F
• I-Mab Announces Underwritten Offering of ADSs — 6-K · Aug 4, 2025 Risk: medium
  On August 1, 2025, I-Mab entered into an underwriting agreement with Leerink Partners LLC for an underwritten offering of 33,333,330 American Depositary Shares
• I-Mab Reports Preliminary Cash of $165.6M as of June 30 — 6-K · Aug 1, 2025 Risk: low
  On August 1, 2025, I-Mab announced its preliminary cash position as of June 30, 2025, expecting to report $165.6 million in cash, cash equivalents, and short-te
• I-Mab Subsidiary Enters Equity Purchase Agreement — 6-K · Jul 17, 2025 Risk: medium
  On July 17, 2025, I-Mab's wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited, entered into an Equity Purchase Agreement. The filing does not specify the
• I-Mab Amends Prospectus for $21M Share Offering — 6-K · Jul 11, 2025 Risk: low
  On July 11, 2025, I-Mab filed an amendment to its prospectus, originally dated May 15, 2025. This amendment pertains to the offer and sale of up to $21,000,000
• I-Mab Presents Positive Givastomig Phase 1b Data at ESMO GI — 6-K · Jul 2, 2025 Risk: medium
  I-Mab announced on July 2, 2025, positive Phase 1b dose escalation data for its drug Givastomig. The data, presented at ESMO GI, shows Givastomig in combination
• I-Mab Presents Positive Givastomig Data at ESMO — 6-K · Jun 26, 2025 Risk: medium
  I-Mab announced positive Phase 1b dose escalation data for Givastomig in combination with immunochemotherapy for first-line gastric cancer patients on June 26,
• I-Mab Regains Nasdaq Minimum Bid Price Compliance — 6-K · Jun 12, 2025 Risk: low
  I-Mab announced on June 12, 2025, that it has regained compliance with the Nasdaq minimum bid price requirement. This means the company's stock price has met th
• I-Mab Files Investor Presentation for June 2025 — 6-K · Jun 2, 2025 Risk: low
  I-Mab filed a Form 6-K on June 2, 2025, to report an investor presentation dated June 2, 2025. The filing includes Exhibit 99.1, which is the investor presentat
• I-Mab Appoints Dr. Sean Cao to Board of Directors — 6-K · May 30, 2025 Risk: low
  On May 28, 2025, I-Mab appointed Dr. Sean Cao as an independent member of its Board of Directors. Dr. Cao will also serve on the Audit Committee and the Compens
• I-Mab Reports Q1 2025 Financial Results — 6-K · May 15, 2025 Risk: low
  I-Mab announced its unaudited financial results for the three months ended March 31, 2025, on May 15, 2025. The company, headquartered in Rockville, MD, is a fo
• I-Mab Files 6-K Report for April 2025 — 6-K · Apr 30, 2025 Risk: low
  On April 30, 2025, I-Mab filed a Form 6-K, attaching a press release dated April 30, 2025. This filing is for the month of April 2025 and indicates that I-Mab i
• I-Mab Files Investor Presentation on April 4, 2025 — 6-K · Apr 4, 2025 Risk: low
  I-Mab filed a Form 6-K on April 4, 2025, to report an investor presentation dated April 4, 2025. The filing includes Exhibit 99.1, which is the investor present
• I-Mab Files 2024 Annual Report — 20-F · Apr 3, 2025 Risk: medium
  I-Mab filed its 20-F for the fiscal year ending December 31, 2024, reporting on its operations and financial status. The company, incorporated in E9 and headqua
• I-Mab Files Form 6-K for S-8 Registration — 6-K · Mar 21, 2025 Risk: low
  I-Mab filed a Form 6-K on March 21, 2025, to incorporate by reference its registration statement on Form S-8 (File No. 333-279842). This filing relates to the c
• I-Mab Files 6-K, Includes March 7 Press Release — 6-K · Mar 7, 2025 Risk: low
  I-Mab filed a Form 6-K on March 7, 2025, to report a press release dated March 7, 2025. The filing includes Exhibit 99.1, which is the press release itself. The
• I-Mab Files Investor Presentation on Feb 27, 2025 — 6-K · Feb 27, 2025 Risk: low
  I-Mab filed a Form 6-K on February 27, 2025, to report an investor presentation dated February 27, 2025. The filing includes Exhibit 99.1, which is the investor
• I-Mab Announces Workforce Reduction Amid Pipeline Reprioritization — 6-K · Jan 29, 2025 Risk: medium
  On January 28, 2025, I-Mab (the "Company") completed a workforce reduction as part of its "Realignment Plan." This reduction aims to right-size the organization
• I-Mab Files Investor Presentation for January 13, 2025 — 6-K · Jan 13, 2025 Risk: low
  I-Mab filed a Form 6-K on January 13, 2025, to report its investor presentation from January 13, 2025. The filing includes Exhibit 99.1, which is the investor p
• I-Mab Board Member Buys Company Shares — 6-K · Jan 8, 2025 Risk: low
  On January 8, 2025, I-Mab announced that a member of its Board of Directors, Wei Fu, made open market purchases of the company's American Depositary Shares (ADS
• I-Mab Prioritizes Givastomig as Lead Clinical Program — 6-K · Jan 6, 2025 Risk: medium
  I-Mab announced on January 6, 2025, that it is prioritizing Givastomig as its lead clinical program. This decision involves restructuring its research and devel
• I-Mab Files Investor Presentation on Dec 3, 2024 — 6-K · Dec 3, 2024 Risk: low
  I-Mab filed a Form 6-K on December 3, 2024, to report its investor presentation dated December 3, 2024. The filing includes Exhibit 99.1, which is the investor
• I-Mab Files Q3 2024 Financial Results — 6-K · Nov 14, 2024 Risk: low
  I-Mab announced its financial results for the three and nine months ended September 30, 2024, on November 14, 2024. The company, headquartered in Rockville, MD,
• I-Mab Appoints Dr. Sean Fu as Permanent CEO — 6-K · Nov 6, 2024 Risk: low
  I-Mab announced on November 6, 2024, the appointment of Dr. Sean Xi-Yong Fu as its permanent Chief Executive Officer, effective November 1, 2024. Dr. Fu had pre
• I-Mab Wins Jury Verdict in Trade Secret Misappropriation Case — 6-K · Nov 5, 2024 Risk: medium
  I-Mab announced a jury trial verdict on November 5, 2024, concerning a portion of its ongoing litigation against Inhibrx, Inc. and Dr. Brendan Eckelman. The tri
• I-Mab Files Q3 2024 Investor Presentation — 6-K · Oct 24, 2024 Risk: low
  I-Mab, a biopharmaceutical company, filed a Form 6-K on October 24, 2024, to report its Q3 2024 investor presentation. The filing includes an investor presentat
• I-Mab Director Resigns, New Director Appointed — 6-K · Sep 23, 2024 Risk: low
  I-Mab announced that Mr. Shuai Chen resigned from its Board of Directors, effective September 18, 2024, due to personal reasons. The Board has appointed Mr. Lie
• I-Mab Presents Updated Givastomig Data at ESMO 2024 — 6-K · Sep 16, 2024 Risk: medium
  I-Mab presented updated Phase 1 data for its drug candidate Givastomig at the ESMO 2024 conference on September 16, 2024. The data pertains to the drug's effica
• I-Mab Enters Secondment Agreement with ABio-X Holdings — 6-K · Aug 30, 2024 Risk: low
  I-Mab announced on August 30, 2024, that it entered into a Secondment Agreement with ABio-X Holdings, Inc. This agreement follows the Company Board's prior appr
• I-Mab Files Mid-Year 2024 Financial Update — 6-K · Aug 28, 2024 Risk: low
  On August 28, 2024, I-Mab filed a Form 6-K to furnish a press release announcing its mid-year 2024 financial results. The filing provides an update on the compa
• I-Mab Changes Auditors from PwC China to PwC US — 6-K · Aug 7, 2024 Risk: low
  On August 6, 2024, I-Mab's Audit Committee approved the change of its independent registered public accounting firm. PricewaterhouseCoopers Zhong Tian LLP (PwC
• I-Mab Announces New CFO — 6-K · Jul 15, 2024 Risk: low
  I-Mab announced leadership transitions on July 15, 2024. Joseph Skelton has been appointed as the Chief Financial Officer. The company is a biopharmaceutical co
• I-Mab Files 6-K with Investor Presentation and Press Release — 6-K · Jun 6, 2024 Risk: low
  I-Mab, a biopharmaceutical company, filed a Form 6-K on June 6, 2024, to report an investor presentation dated June 5, 2024, and a press release dated June 6, 2

Risk Profile

Risk Assessment: Of NBP's 49 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 37 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Wei Fu
• Dr. Robert Lenz
• Ms. Xin Li
• Dr. Sean Cao
• Dr. Sean Xi-Yong Fu
• Dr. Brendan Eckelman
• Shuai Chen
• Lielie Zhang
• Joseph Skelton

Top Tags

6-K (7) · sec-filing (7) · investor-relations (6) · filing (5) · registration-statement (5) · presentation (5) · press-release (3) · agreement (3) · financial-update (3) · management-change (3)

Key Numbers

• Submission Size: 693270 bytes — Total size of the complete submission text file.
• Reporting Period: Q3 2025 — The filing covers financial and corporate information up to the third quarter of 2025.
• Commission File Number: 001-39173 — Identifies the company's filing with the SEC
• ADSs Offered: 33,333,330 — Represents the total number of American Depositary Shares being issued in the underwritten offering.
• Cash and Equivalents: $165.6M — Preliminary cash position as of June 30, 2025, indicating financial liquidity.
• Share Offering Amount: $21.0M — Maximum value of ordinary shares I-Mab is offering for sale.
• Minimum Bid Price: $1.00 — The threshold I-Mab needed to meet to regain compliance with Nasdaq listing rules.
• Fiscal Year End: 2024-12-31 — The period covered by the 20-F filing.
• Filing Date: 2025-04-03 — The date the 20-F was submitted to the SEC.
• Lemzoparlimab License Start: 2022-08-01 — Indicates the period related to the AbbVie licensing agreement.

Related Companies

IMAB · INHX

Frequently Asked Questions